

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Targeted T cells for anticancer therapy	<p>A study in mice suggests that T cells modified to target mesothelin may be useful for treating cancer. Mesothelin is overexpressed on many human tumors. Lentiviral vectors were used to generate mesothelin-targeting T cells that had higher circulation times and expression of the targeting molecule than earlier modified T cells. In mice with established human mesothelioma tumors, intratumoral injections of the mesothelin-targeting T cells lowered tumor burden compared with that seen using control vectors or saline ($p < 0.0001$). Next steps could include evaluating the safety and efficacy of the modified T cell therapy in additional preclinical cancer models.</p> <p>SciBX 2(8); doi:10.1038/scibx.2009.341 Published online Feb. 26, 2009</p>	Patent and licensing status unavailable	<p>Carpenito, C. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Feb. 9, 2009; doi:10.1073/pnas.0813101106 Contact: Carl H. June, University of Pennsylvania School of Medicine, Philadelphia, Pa. e-mail: cjune@exchange.upenn.edu</p>